...
首页> 外文期刊>Bioinformatics >iFad: an integrative factor analysis model for drug-pathway association inference{dagger}.
【24h】

iFad: an integrative factor analysis model for drug-pathway association inference{dagger}.

机译:iFad:用于药物-途径关联推断的综合因素分析模型{dagger}。

获取原文
获取原文并翻译 | 示例
           

摘要

MOTIVATION: Pathway-based drug discovery considers the therapeutic effects of compounds in the global physiological environment. This approach has been gaining popularity in recent years because the target pathways and mechanism of action for many compounds are still unknown, and there are also some unexpected off-target effects. Therefore, the inference of drug-pathway associations is a crucial step to fully realize the potential of system-based pharmacological research. Transcriptome data offer valuable information on drug-pathway targets because the pathway activities may be reflected through gene expression levels. Hence, it is of great interest to jointly analyze the drug sensitivity and gene expression data from the same set of samples to investigate the gene-pathway-drug-pathway associations. RESULTS: We have developed iFad, a Bayesian sparse factor analysis model to jointly analyze the paired gene expression and drug sensitivity datasets measured across the same panel of samples. The model enables direct incorporation of prior knowledge regarding gene-pathway and/or drug-pathway associations to aid the discovery of new association relationships. We use a collapsed Gibbs sampling algorithm for inference. Satisfactory performance of the proposed model was found for both simulated datasets and real data collected on the NCI-60 cell lines. Our results suggest that iFad is a promising approach for the identification of drug targets. This model also provides a general statistical framework for pathway-based integrative analysis of other types of -omics data. AVAILABILITY: The R package 'iFad' and real NCI-60 dataset used are available at http://bioinformatics.med.yale.edu/group/. CONTACT: hongyu.zhao@yale.edu SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
机译:动机:基于途径的药物发现考虑了化合物在全球生理环境中的治疗作用。近年来,由于许多化合物的靶标通路和作用机理仍未知,并且还存在一些出乎意料的脱靶作用,因此该方法已变得越来越流行。因此,推论药物-途径的联系是充分实现基于系统的药理学研究潜力的关键步骤。转录组数据提供了有关药物通路靶标的有价值的信息,因为通路活性可能通过基因表达水平反映出来。因此,联合分析来自同一组样品的药物敏感性和基因表达数据以研究基因-途径-药物-途径之间的关联是非常有意义的。结果:我们开发了贝叶斯稀疏因子分析模型iFad,以共同分析在同一组样本中测得的配对基因表达和药物敏感性数据集。该模型能够直接整合有关基因途径和/或药物途径关联的现有知识,以帮助发现新的关联关系。我们使用折叠的吉布斯采样算法进行推理。对于模拟数据集和在NCI-60细胞系上收集的真实数据,发现拟议模型的性能令人满意。我们的结果表明,iFad是鉴定药物靶标的有前途的方法。该模型还为其他类型的组学数据的基于路径的综合分析提供了一个通用的统计框架。可用性:使用的R软件包“ iFad”和实际的NCI-60数据集可从http://bioinformatics.med.yale.edu/group/获得。联系人:hongyu.zhao@yale.edu补充信息:补充数据可从Bioinformatics在线获得。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号